irishpaddy, I believe the key to optimizing Vascepa sales is and will
always be, BP ownership. If I were a BP owning AMRN I would concentrate
initially on developing Europe with EMA approval. I would use the legal
system to delay or hinder the launch of generics. Only if the BP had
a generic operation in the US would I launch a generic, otherwise, I
would stop promoting Vascepa in the US if generics could supply enough
product to destroy Vascepa sales.
Next, I would determine if the Mochida one a day version of Vascepa
could be used in a way (assuming it could get the Reduce-It indication
for the label) that would prevent a generic drug to be used in its
stead. (Don't know if that would work but I would want to find out.)
Having a "branded" next generation Vascepa drug might have patents to
extend the patent life of the product. Thus, would be used initially
in the US, and then be used in Europe and ROW if or when needed there.
Hopefully, if BP acquires AMRN should Vascepa prove useful in treating
COVID-19 or various influenzas they should be able to benefit from it
as well as seek out other indications. Nestles has a market cap of
$340 billion and they announced a BO of AIMT on Monday for $34.50 in
cash...on the Friday before it was trading at $13. AMRN need a BO!
Market Data 
Markets 
